Title:
セロトニンファミリーの受容体および血液脳関門に関する免疫調節および細胞過程への影響
Document Type and Number:
Japanese Patent JP2005538065
Kind Code:
A
Abstract:
The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling, such as by using fluphenazine, can be used to modulate the immune response, cell proliferation, and apoptosis, among other cell processes. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling. Additionally, methods for the use, identification and production of an inhibitor that does not substantially cross the blood-brain barrier are also provided.
Inventors:
The Ameson, Bradoff Ord A
Anna Maria, Trety Akoba
Davidson, Harold Carter
Anna Maria, Trety Akoba
Davidson, Harold Carter
Application Number:
JP2004513473A
Publication Date:
December 15, 2005
Filing Date:
June 17, 2003
Export Citation:
Assignee:
Philadelphia Health and Education Corporation Corporation
International Classes:
A61K31/4245; A61K31/437; A61K31/4375; A61K31/4439; A61K31/444; A61K31/445; A61K31/496; A61K31/505; A61K31/517; A61K31/519; A61K31/5415; A61K31/55; A61K45/00; A61P1/04; A61P3/10; A61P13/00; A61P15/00; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P27/02; A61P29/00; A61P37/02; C07K14/705; C12N5/07; C12N5/0781; C12N5/0783; C12Q1/02; G01N33/15; G01N33/50; G01N33/566; (IPC1-7): A61K45/00; A61K31/4245; A61K31/437; A61K31/4375; A61K31/4439; A61K31/444; A61K31/445; A61K31/496; A61K31/517; A61K31/5415; A61K31/55; A61P1/04; A61P3/10; A61P13/00; A61P15/00; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P27/02; A61P29/00; A61P37/02; C12N5/06; C12Q1/02; G01N33/15; G01N33/50
Domestic Patent References:
| JPH05502217A | 1993-04-22 |
Foreign References:
| US3058979A | 1962-10-16 |
Other References:
CSNC200900363012, 小池 隆夫, "免疫抑制剤の自己免疫疾患に対する効果", 医学のあゆみ, 第１６６巻, ｐ．５６６
CSNC200900302034, 近藤 啓文, "免疫抑制剤", 医学のあゆみ, 第１６１巻, ｐ．６９４−６９８, 三浦 裕士 医歯薬出版株式会社
CSNC200900283005, 駒田 富佐夫, "新しい免疫抑制剤開発の動向", 医学のあゆみ, 第１６０巻, ｐ．１７３−１７６
JPN6009036890, ＳＣＨＬＥＵＮＩＮＧ，Ｍ． ｅｔ ａｌ, "Ｉｎｈｉｂｉｔｉｏｎ ｏｆ ｃｙｃｌｏｓｐｏｒｉｎ Ａ／ＦＫ５０６ ｒｅｓｉｓｔａｎｔ， ｌｙｍｐｈｏｋｉｎｅ−ｉｎｄｕｃｅｄ Ｔ−ｃｅｌｌ ａｃｔｉｖａｔｉｏｎ ｂｙ ｐｈｅｎｏｔｈｉａｚｉｎｅ ｄ", Ｎａｕｎｙｎ Ｓｃｈｍｉｅｄｅｂｅｒｇｓ Ａｒｃｈ Ｐｈａｒｍａｃｏｌ, 1994, Ｖｏｌ．３５０， Ｎｏ．１, ｐ．１００−３
JPN6009036891, ＲＡＵＳＫＩ，Ａ． ｅｔ ａｌ, "Ｄｏｐａｍｉｎｅｒｇｉｃ ｍｏｄｕｌａｔｉｏｎ ｏｆ ｈｕｍｏｒａｌ ｉｍｍｕｎｅ ｒｅｓｐｏｎｓｅ ｉｎ ｔｈｅ ｒａｔ", Ｉｕｇｏｓｌａｖｉｃａ Ｐｈｙｓｉｏｌｏｇｉｃａ ｅｔ Ｐｈａｒｍａｃｏｌｏｇｉｃａ Ａｃｔａ, 1995, Ｖｏｌ．３１， Ｎｏ．１, ｐ．１２３−９
JPN6009036892, 田中千賀子編, ＮＥＷ薬理学（改訂第３版）, 19970801, ｐ．２６, JP, 株式会社 南江堂
JPN6009036893, ＨＥＲＲＩＣＫ−ＤＡＶＩＳ，Ｋ． ｅｔ ａｌ, "Ｉｎｖｅｒｓｅ ａｇｏｎｉｓｔ ａｃｔｉｖｉｔｙ ｏｆ ａｔｙｐｉｃａｌ ａｎｔｉｐｓｙｃｈｏｔｉｃ ｄｒｕｇｓ ａｔ ｈｕｍａｎ ５−ｈｙｄｒｏｘｙｔｒｙｐｔａｍｉｎｅ２Ｃ ｒｅｃｅｐｔｏｒｓ", Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ, 2000, Ｖｏｌ．２９５， Ｎｏ．１, ｐ．２２６−３２
CSNC200900302034, 近藤 啓文, "免疫抑制剤", 医学のあゆみ, 第１６１巻, ｐ．６９４−６９８, 三浦 裕士 医歯薬出版株式会社
CSNC200900283005, 駒田 富佐夫, "新しい免疫抑制剤開発の動向", 医学のあゆみ, 第１６０巻, ｐ．１７３−１７６
JPN6009036890, ＳＣＨＬＥＵＮＩＮＧ，Ｍ． ｅｔ ａｌ, "Ｉｎｈｉｂｉｔｉｏｎ ｏｆ ｃｙｃｌｏｓｐｏｒｉｎ Ａ／ＦＫ５０６ ｒｅｓｉｓｔａｎｔ， ｌｙｍｐｈｏｋｉｎｅ−ｉｎｄｕｃｅｄ Ｔ−ｃｅｌｌ ａｃｔｉｖａｔｉｏｎ ｂｙ ｐｈｅｎｏｔｈｉａｚｉｎｅ ｄ", Ｎａｕｎｙｎ Ｓｃｈｍｉｅｄｅｂｅｒｇｓ Ａｒｃｈ Ｐｈａｒｍａｃｏｌ, 1994, Ｖｏｌ．３５０， Ｎｏ．１, ｐ．１００−３
JPN6009036891, ＲＡＵＳＫＩ，Ａ． ｅｔ ａｌ, "Ｄｏｐａｍｉｎｅｒｇｉｃ ｍｏｄｕｌａｔｉｏｎ ｏｆ ｈｕｍｏｒａｌ ｉｍｍｕｎｅ ｒｅｓｐｏｎｓｅ ｉｎ ｔｈｅ ｒａｔ", Ｉｕｇｏｓｌａｖｉｃａ Ｐｈｙｓｉｏｌｏｇｉｃａ ｅｔ Ｐｈａｒｍａｃｏｌｏｇｉｃａ Ａｃｔａ, 1995, Ｖｏｌ．３１， Ｎｏ．１, ｐ．１２３−９
JPN6009036892, 田中千賀子編, ＮＥＷ薬理学（改訂第３版）, 19970801, ｐ．２６, JP, 株式会社 南江堂
JPN6009036893, ＨＥＲＲＩＣＫ−ＤＡＶＩＳ，Ｋ． ｅｔ ａｌ, "Ｉｎｖｅｒｓｅ ａｇｏｎｉｓｔ ａｃｔｉｖｉｔｙ ｏｆ ａｔｙｐｉｃａｌ ａｎｔｉｐｓｙｃｈｏｔｉｃ ｄｒｕｇｓ ａｔ ｈｕｍａｎ ５−ｈｙｄｒｏｘｙｔｒｙｐｔａｍｉｎｅ２Ｃ ｒｅｃｅｐｔｏｒｓ", Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ, 2000, Ｖｏｌ．２９５， Ｎｏ．１, ｐ．２２６−３２
Attorney, Agent or Firm:
Heikichi Odashima